###### Significance Statement

Alterations in white matter microstructure measured with magnetic resonance imaging (MRI) were associated with poor antidepressant response. In this trial, patients suffering from depression resistant to pharmacological treatment underwent a series of electroconvulsive therapy with right unilateral stimulation. Compared with baseline, an increase in axial diffusivity was observed in the right internal capsule using diffusion weighted magnetic resonance imaging after treatment. This effect was stronger in the right hemisphere, which suggests that the effect of electroconvulsive therapy on white matter microstructure depends on electrode placement. The relationship of changes in diffusivity metrics in motor pathways and clinical outcomes in treatment-resistant depression needs to be explored in controlled studies.

Introduction {#s1}
============

Electroconvulsive therapy (ECT) constitutes one of the most effective treatment options for patients suffering from depression who do not respond to psychotropic medication or psychotherapy ([@CIT0005]). Alterations of white matter microstructure assessed using diffusion tensor imaging (DTI) have been reported in depression, and white matter structures have emerged as potential targets for deep brain stimulation in treatment-resistant cases ([@CIT0006]; [@CIT0012]). The most frequently investigated outcome measure, fractional anisotropy (FA), a marker for the strength of directionality of diffusion, is reduced in depressed patients, and more pronounced reductions were found to be related to an insufficient treatment response ([@CIT0008]; [@CIT0009]) and cognitive impairments ([@CIT0016]). On the other hand, longitudinal studies following patients over the course of antidepressant treatment could show an increase in FA ([@CIT0029]) in some studies to levels comparable with healthy control participants ([@CIT0018]). A handful of trials assessed the effects of ECT on white matter microstructure in depressive patients ([@CIT0023]; [@CIT0018]; [@CIT0030]; [@CIT0021]; [@CIT0004]; [@CIT0025]). The first investigation reported an increase in FA after ECT in frontal white matter of 8 patients diagnosed with late-life depression ([@CIT0023]). However, only 3 studies have conducted comprehensive analyses of changes in diffusivity metrics after ECT in the whole brain using tract-based spatial statistics (TBSS). One of these studies investigated FA and found no differences after ECT in 21 patients ([@CIT0021]). The other 2 studies included an extended analysis of directional diffusivity. In animal models, the corresponding metrics, axial (AD) and radial (RD) diffusivity, were shown to allow for the differentiation of alterations in axonal integrity (decreased AD) and myelin disruption (increased RD), respectively ([@CIT0028]). The first study reported increases in FA and decreases in RD in bilateral anterior cingulum, forceps minor, and the left superior longitudinal fasciculus after ECT in 20 patients. Moreover, a decrease in mean diffusivity (MD) was detected in the left anterior cingulum, anterior thalamic radiation, and forceps minor ([@CIT0018]). The second study found an increase in MD in the posterior limb of the internal capsule (PLIC) and the inferior longitudinal fasciculus among several other regions of the right hemisphere in 29 patients ([@CIT0025]). Furthermore, the more recent study could not replicate associations between changes in diffusivity metrics and treatment response ([@CIT0025]). As evident from these results, more information on the effect of ECT on white matter microstructure is desirable.

Aims of the Study {#s2}
-----------------

The aim of this study was to quantify changes in white matter microstructure after electroconvulsive therapy using whole-brain, tract-based spatial statistics analysis of diffusion weighted imaging data acquired in patients suffering from unipolar, treatment-resistant depression (TRD), a population that poses a serious challenge in clinical practice with a pressing need for improved therapeutic options. New insight on the lateralization of treatment effects was expected from the exclusively right-unilateral electrode placement employed.

METHODS {#s3}
=======

Participants and Study Design {#s4}
-----------------------------

In this interventional pre-post study, adult patients (18--60 years) suffering from a severe and treatment-resistant depressive episode (ICD-10: F32.2, F32.3, F33.2, F33.3) and a 17-item Hamilton Depression Rating Scale (HAM-D) score ≥23 were included. Recruitment was carried out at the inpatient clinic of the Department of Psychiatry and Psychotherapy at the Medical University of Vienna. Exclusion criteria were any contraindication to magnetic resonance imaging (MRI), metallic implants in the head, history of an ECT series, or diagnosis of bipolar affective disorder, schizoaffective disorder, or schizophrenia. Clinical diagnoses were supported by structured clinical interviews for DSM IV. Treatment resistance was defined by insufficient response to at least 2 adequate antidepressant treatment trials in the current episode. Adequate trials were defined as administration of approved antidepressants or augmentation therapies recommended in treatment guidelines for at least 2 weeks ([@CIT0005]). Ten days prior to MR scans, patients were maintained under stable medication, except benzodiazepines as rescue medication. Physical examination, thoracic X-ray, routine laboratory tests, electrocardiography, and urine screening tests for substance abuse and pregnancy were carried out to ascertain general health and obtain clearance for anesthesia. All patients provided written informed consent. All study procedures were carried out according to good clinical practice guidelines and the Declaration of Helsinki of 1975 as revised in 2008 and approved by the Ethics Committee of the Medical University of Vienna. The study was registered before start of recruitment at clinicaltrials.gov (NCT02379767). Changes in T1 weighted structural MRI outcomes in these patients were previously reported ([@CIT0010]).

Electroconvulsive Therapy {#s5}
-------------------------

Each patient underwent an ECT series consisting of at least 8 sessions with right unilateral stimulations according to standard operating procedures established at the clinic. Post-ECT assessments were scheduled after 8 sessions. Additional ECT sessions were performed based on continuous clinical evaluation. Due to availability of MRI slots, 4 patients who continued ECT treatment received more than 8 sessions before undergoing post-ECT assessments. A maximum of 3 sessions per week were performed. The Thymatron System IV device (Somatics, LLC., Lake Bluff, IL) was used with right unilateral electrode placement and a brief pulse width (0.5 milliseconds). The stimulation dose was set to 50 mC (10%) during the first treatment and resulted in an adequate seizure in all patients, as evidenced by seizure duration, amplitude, ictal coherence, and post-ictal suppression. The second stimulation was performed at thrice the seizure threshold and further increased in case of inadequate seizure quality. Electrocardiography, electroencephalography, and electromyography of 1 forearm were performed during treatment. Methohexital and succinylcholine were applied for anesthesia and relaxation, respectively. Ongoing medication with putative effects on blood pressure or seizure quality was administered after ECT sessions on treatment days.

Diffusion Tensor Imaging {#s6}
------------------------

DTI scans were acquired on a 3T PRISMA MR Scanner (Siemens Medical, Erlangen, Germany) with a 64-channel head coil. Each patient received 2 scans in short succession (1--5 days) before ECT and 1 scan at least 1 day after the last ECT session (median: 1 day, maximum: 13 days). A single-shot, diffusion-weighted, echo planar imaging sequence was acquired (TE, 76 milliseconds; TR, 9400 milliseconds; flip angle, 90°; image resolution: 1.6 mm isotropic; b value, 800 s/mm^2^; 75 axial slices) in 64 diffusion-encoding directions and 5 nondiffusion b0 images. The Functional MRI of the Brain software library (FMRIB Software Library version 5.0.11; <http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/>) and TBSS ([@CIT0026]) were used with default parameters for calculation of FA, MD, AD, and RD according to standard definitions, as done previously by our group ([@CIT0014], [@CIT0015]). AD was calculated as the eigenvalue of the primary eigenvector, RD as the average of the 2 smaller eigenvalues, and MD as the average of all 3 eigenvalues. FA was calculated as the square root of the ratio between the sum of squared differences between each eigenvalue and MD and twice the sum of each eigenvalue squared. Nonbrain tissue was removed with the brain extraction tool. Imaging data were corrected for eddy current artifacts, head movement between frames, and distortions using the eddy_cuda command ([@CIT0001]) and outlier replacement ([@CIT0002]) as implemented in FSL. The tensor model was fitted using dtifit and the rotated b-vectors generated during the eddy current correction step. For registration of data to Montreal Neurological Institute (MNI) space, the mean FA image was used to create a skeleton of white matter tracts to which individual FA images were mapped. The same transformations were applied to individual AD, RD, and MD images. Raw data and the results of all processing steps were visually inspected to ensure high data quality.

Statistical Analysis {#s7}
--------------------

Analysis of longitudinal effects of ECT on the diffusivity metrics (FA, MD, AD, and RD) was performed voxel-wise using nonparametric permutation tests implemented in FSL. Paired *t* tests were calculated between pre-ECT and post-ECT data. To this end, data from the 2 MR scans acquired before ECT were averaged. To test for the asymmetry of the effect, clusters with significant changes in one of the diffusivity metrics were mirrored to the other hemisphere. As the white matter skeleton is not entirely symmetrical, each mirrored voxel was assigned to its nearest neighbor on the skeleton based on Euclidean distance. Subsequently, the change in the respective diffusivity metric between each significant cluster and its mirrored counterpart was compared by nonparametric permutation tests implemented in Matlab (500 permutations). Furthermore, the associations of changes in diffusivity metrics in significant clusters with changes in HAM-D scores, the interval between the last treatment and imaging procedures, and treatment parameters (number of sessions, average seizure duration, average dose) were assessed by calculation of Pearson correlation coefficients and inspection of scatterplots. The role of the effect of ECT on regional brain volumes reported in our previous work ([@CIT0010]) was assessed by correlating the changes in diffusivity metrics in significant clusters with changes in volumes in adjacent structures. Regional brain volumes were obtained using automated parcellation of T1 weighted data acquired during the same MRI sessions as diffusion weighted imaging using FreeSurfer 6.0 (Harvard Medical School, Boston, MA; <http://surfer.nmr.mgh.harvard.edu/>). Further information can be found in our previous publication ([@CIT0010]). For completeness, the correlation between diffusivity metrics at baseline and changes in HAM-D scores was assessed voxel-wise using nonparametric permutation tests. The statistical significance level was set at α ≤ 0.05 corrected for family wise error (FWE) using threshold-free cluster enhancement ([@CIT0027]). Significant clusters were matched with white matter tracts in the DTI-81 white matter atlas of the International Consortium for Human Brain Mapping ([@CIT0019]). Trend-level effects with *P*~FWE~ ≤ .1 were reported in the supplement.

RESULTS {#s8}
=======

Clinical Data {#s9}
-------------

A total 16 patients suffering from TRD were enrolled in this trial. One patient had to be excluded from analysis due to acquisition of data on a different MRI scanner. Another patient dropped out because of a phobic reaction in the scanner. For 1 patient, no post-ECT MR data were available. Consequently, DTI data for longitudinal analysis of ECT effects on white matter microstructure was available from 13 patients (aged 48.9 ± 8.4 years, 10 female). Among the final 13 patients, 2 were diagnosed with psychotic symptoms and 12 were suffering from recurrent depressive disorder. Mean HAM-D was 25.4 ± 3.5 at inclusion and 6.8 ± 4.3 at completion. A total of 8.6 ± 1.0 (maximum 11) ECT sessions were applied before post-ECT scans, and a seizure duration of 42.5 ± 10.4 seconds was recorded on average. Nine patients were classified as remitters with a HAM-D ≤7, and only 1 patient did not respond (HAM-D reduction \<50%). Each patient was receiving psychopharmacological treatment with a selective serotonin reuptake inhibitor (n = 10) or a serotonin-norepinephrine reuptake inhibitor (n = 5) at inclusion. Four patients had been prescribed noradrenergic and specific serotonergic antidepressants, and 1 patient was taking amitriptyline. Augmentation of antidepressant therapy had been performed with atypical antipsychotics in 10 patients and lamotrigine in 3 patients. A detailed tabulation of exact dosages, diagnoses, and ECT treatment parameters can be found in a previous paper on this patient sample published under an open-access license ([@CIT0010]).

Effects of ECT on Diffusivity Metrics {#s10}
-------------------------------------

A significant increase in AD (*P*~FWE~ ≤ .05, peak *t* value = 4.89, MNI-coordinates (xyz): 11\|6\|2) was observed in a cluster extending from the posterior limb of the right internal capsule to the posterior part of the anterior limb of the internal capsule ([Figure 1](#F1){ref-type="fig"}). Changes in AD in this cluster were significantly higher than changes in AD in the corresponding areas in the left hemisphere (*P* \< .05). No correlations of changes in AD in this cluster with changes in HAM-D scores, treatment parameters, or the interval between the last ECT session and MRI scans were found. No correlations between the changes in AD in this cluster with changes in the volumes of the adjacent gray matter structures (putamen, globus pallidus, thalamus, and caudate nucleus) were observed.

![Significant changes in axial diffusivity after electroconvulsive therapy (ECT). A cluster with increased axial diffusivity is overlaid on the mean fractional anisotropy (FA) skeleton and a T1 weighted standard brain (*P* family wise error \[*P*~FWE~\] \< .05, MNI-coordinates (xyz): 11\|-4\|2).](pyz059f0001){#F1}

Trend-level effects of ECT on AD, MD, and RD are reported in the supplement (*P*~FWE~ ≤ .1; [supplementary Figure 1](#sup1){ref-type="supplementary-material"}). Briefly, widespread increases in AD and MD could be observed in white matter structures of both hemispheres, although marked asymmetry was present with lower changes in the left hemisphere. Trend-level increases in RD were observed exclusively in the right hemisphere. No significant or trend-level effects of ECT on FA could be found.

No correlations between diffusivity metrics at baseline and changes in HAM-D scores were found.

Discussion {#s11}
==========

We observed an increase in AD after ECT, which was predominantly located in the right PLIC. This white matter structure is composed to a large fraction of efferent fibers running in the pyramidal tract ([@CIT0011]). Acute lesions identified using diffusion weighted imaging were associated with poor motor outcome and hemispatial neglect after stroke ([@CIT0024]; [@CIT0017]). The notion of alterations in motor pathways in major depression is further supported by a study which reported increased MD values in cortico-cortical connections of the supplementary- with the primary- and pre-motor cortices of depressed patients ([@CIT0020]). A reduction in AD in the right PLIC was reported in a large sample of treatment-naïve patients suffering from a first episode of major depression ([@CIT0013]). Our results suggest that this alteration might be reversed with ECT. Alternatively, reduced AD in the right PLIC of depressed patients, and its increase with treatment might be a correlate of depressive symptoms, perhaps psychomotor retardation specifically. However, neither the observed change in AD nor diffusivity metrics at baseline were correlated with clinical response. While this might suggest that changes in diffusivity are not related to the antidepressant effects of ECT or that diffusion weighted imaging might not be useful in the prediction of the efficacy of ECT in individual patients, such conclusions can only be drawn with caution, as the lack of significant correlations could be a false negative result due to the limited sample size which only allows for the detection of strong correlations. Therefore, whether diffusivity metrics at baseline or changes after treatment are related to the clinical outcome of TRD patients needs to be explored in large controlled trials.

An indication that a part of the effect of ECT on DTI metrics may be attributed to direct electrical stimulation can be derived from the lateralization of significant changes to the side of electrode placement. Despite the lateralization of changes in gray matter structures to the right hemisphere reported previously in the same patients ([@CIT0010]), no associations of the change in AD in the right PLIC with changes in the volume of adjacent gray matter structures were observed in the current analysis. This suggests that the analysis of changes in white matter diffusivity, in addition to changes in regional brain volumes, provides complimentary information on the effects of ECT in individual patients. The lack of significant effects on AD in the literature may be due to the fact that previous studies investigating ECT effects on all diffusivity metrics were performed using MRI systems with lower peak gradient strength than the 80 mT/m of the 3T PRISMA MR Scanner or fewer diffusion directions ([@CIT0018]; [@CIT0025]). Nevertheless, the significant increase in MD reported in the more recent study shows a high overlap with our results, especially concerning the right PLIC. Furthermore, the lack of significant effects on FA in the current data is in line with 2 of the 3 previous TBSS studies ([@CIT0021]; [@CIT0025]). The fact that the observed increases in AD did not translate into an increase in FA could be attributed to the trend-level increase in RD in the right hemisphere. A possible interpretation of an increase in AD is strengthening of axonal structures, perhaps due to the engagement of tracts by electrical stimulation or seizure activity. However, the observed trend-level increases in MD and RD imply that the reduction in diffusion barriers after ECT might be omnidirectional. In temporal lobe epilepsy, increases in MD ipsilateral to the focus have been observed following seizures. These changes were negatively correlated with the interval between imaging and the last seizure and have been attributed to transient vasogenic edema ([@CIT0007]). In the current study, no correlations between the increase in AD in the right PLIC and the interval between the last ECT session and imaging or any treatment or seizure parameters were found. Preclinical evidence for alterations in the permeability of the blood brain barrier due to experimentally induced seizures is available ([@CIT0022]). While a role of the intra-ictal hypertensive surge for the disruption of the BBB has been suggested ([@CIT0003]), the lateralization of the changes in diffusivity in the present data implicates other mechanisms. Unfortunately, intra-ictal blood pressure was not systematically measured. The neurobiological process underlying the observed effect needs to be determined in postmortem tissue or animal models of ECT, and conclusions concerning the integrity of white matter cannot be drawn from the results of this study. Furthermore, a controlled study with different electrode placements needs to be performed before attributing the lateralized effects to unilateral stimulation.

Several limitations of the current study need to be mentioned. Firstly, the available sample size does not allow for the differentiation of small to medium effect sizes. The power for testing interesting between-patient effects is especially limited such that the chance for false negative results is high for correlation of imaging outcomes with clinical parameters. Based on the study design without a control group, no causal attribution of observed pre-post changes to the treatment can be stated (i.e., the effects may be due to natural tendencies or spontaneous remission). The included patients were taking psychopharmacological drugs, which may have affected the results. However, these were in steady-state before enrollment and many, if not most patients, who undergo ECT are taking medication.

In summary, we observed an increase in axial diffusivity in the PLIC in the right hemisphere of patients who underwent an ECT series with right unilateral stimulation for TRD. This effect was significantly stronger in the right hemisphere. The underlying neurobiological processes need to be scrutinized in postmortem tissue or animal models of ECT.

Supplementary Material
======================

###### 

Click here for additional data file.
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